New drug cocktail targets Hard-to-Treat breast cancer in early trial
NCT ID NCT05673200
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This phase I trial is testing a new drug called ASTX727 (a combination of decitabine and cedazuridine) alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The study aims to find the safest dose and check for side effects. It includes 32 adults whose cancer has spread and who have not responded to other treatments. The trial is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASTX727 (decitabine and cedazuridine) plus paclitaxel and pembrolizumab
- What this could lead to
- If it works, this could lead to a new combination treatment that helps shrink or stabilize metastatic triple-negative breast cancer for longer than current standard care.
- What could go wrong
- This is a very early phase I trial with only 32 participants, so the main goal is safety and dosing—not yet proof of effectiveness. The study is currently suspended, and side effects from combining these drugs could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, 92627, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer